12th May 2015
Nuformix is pleased to announce it has received the first grant of its NXP001 patent for the US territory. Nuformix is pursuing global patent coverage for NXP001 asset, which offers multiple options for future development. Nuformix Chief Executive Officer Dr Dan Gooding said: “Nuformix has already had patents granted in both the US and China for its proprietary cocrystal drugs forms. However, NXP001 is a critical asset for Nuformix, so we’re delighted to see the patent grant in the US. The series of US grants we’ve now received sets a firm precedent for other geographies to follow suit, but also for future patents filings resulting from our discovery and development pipeline. Our appointment of Jeff Lindeman at J. A. Lindeman LLC as our patent agent has proven to be invaluable. These achievements would not be possible without Jeff’s expertise and guidance, and for that we are grateful.”